|Assessment Process Complete
|In combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended
The NCPE do not recommend reimbursement of nab-paclitaxel (Abraxane®).
The HSE has approved reimbursement following confidential price negotiations December 2015